CYP2E1

Across TCGA pan-cancer cohorts, CYP2E1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP2E1 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CYP2E1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP2E1 expression acts as an unfavorable survival marker, although some lineages such as OV and SKCM show a favorable association.

CESC, LUAD, and OV are the cancer types where CYP2E1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.053	0.729	<.001	18	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	18	view →
OV	DFS	Median	II,III,IV	0.506	0.160	.019	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	II,III,IV	1.000	0.824	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP2E1–CESC (DFS)

Open the CESC breakdown →